The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Trabectedin (T) versus adriamycin plus dacarbazine (A-DA) in advanced solitary fibrous tumor (SFT): Results from a phase II randomised clinical study (STRADA).
 
Silvia Stacchiotti
Honoraria - Aadi; Boehringer Ingelheim; Gentili; GlaxoSmithKline; PharmaMar
Consulting or Advisory Role - Agenus; Astex Pharmaceuticals; Bavarian Nordic; Bayer; Boehringer Ingelheim; Daiichi Sankyo; GlaxoSmithKline; Ikena Oncology; MaxiVax; Novartis; PharmaMar; Rain Therapeutics; Regeneron; SERVIER
Research Funding - Advenchen Laboratories (Inst); Amgen (Inst); Bayer (Inst); Blueprint Medicines (Inst); Boehringer Ingelheim (Inst); Daiichi Sankyo (Inst); Deciphera (Inst); Epizyme (Inst); GlaxoSmithKline (Inst); Hutchison MediPharma (Inst); InhibRx (Inst); Karyopharm Therapeutics (Inst); Lilly (Inst); Novartis (Inst); Pfizer (Inst); PharmaMar (Inst); Rain Therapeutics (Inst); SpringWorks Therapeutics (Inst)
Travel, Accommodations, Expenses - PharmaMar
 
Giovanni Grignani
Honoraria - Bayer; Lilly O.; Merck; PharmaMar
Consulting or Advisory Role - Bayer; Lilly O.; Merck; PharmaMar
Research Funding - Bayer; Novartis; PharmaMar
Travel, Accommodations, Expenses - PharmaMar
 
Bruno Vincenzi
Consulting or Advisory Role - abbott; GlaxoSmithKline; Lilly
Speakers' Bureau - PharmaMar
Research Funding - BD Bard
 
Ignazio Carreca
Consulting or Advisory Role - Boehringer Ingelheim; GlaxoSmithKline
 
Emanuela Palmerini
Consulting or Advisory Role - Daiichi Sankyo; Deciphera; SynOX
 
Paola Collini
No Relationships to Disclose
 
Angelo Paolo Dei Tos
Consulting or Advisory Role - Bayer; GlaxoSmithKline; Novartis; PharmaMar
Speakers' Bureau - GlaxoSmithKline; PharmaMar
Travel, Accommodations, Expenses - PharmaMar
 
Gianpaolo Dagrada
No Relationships to Disclose
 
Nadia Zaffaroni
No Relationships to Disclose
 
Alessandro Gronchi
Honoraria - Deciphera; Lilly; Novartis; Pfizer; PharmaMar
Consulting or Advisory Role - Bayer; Lilly; Nanobiotix; Novartis; Pfizer; PharmaMar; SpringWorks Therapeutics
Research Funding - Nanobiotix (Inst); PharmaMar (Inst)
Travel, Accommodations, Expenses - Nanobiotix; PharmaMar
 
Gianluca Ignazzi
Research Funding - Bayer (Inst); Eisai (Inst); GlaxoSmithKline/Tesaro (Inst); PharmaMar (Inst); Roche (Inst)
 
Viviana Appolloni
Research Funding - Bayer (Inst); Eisai (Inst); PharmaMar (Inst); Roche Italy (Inst); Tesaro/GSK (Inst)
 
Matilde Ingrosso
Research Funding - Advenchen Laboratories (Inst); Bayer (Inst); Boehringer Ingelheim (Inst); Daiichi Sankyo (Inst); Deciphera (Inst); Epizyme (Inst); Foghorn Therapeutics (Inst); GlaxoSmithKline (Inst); Hutchison MediPharma (Inst); InhibRx (Inst); Karyopharm Therapeutics (Inst); Novartis (Inst); Pfizer (Inst); PharmaMar (Inst); Rain Oncology (Inst); SpringWorks Therapeutics (Inst)
 
Anna Maria Frezza
No Relationships to Disclose
 
Paolo Giovanni Casali
Research Funding - Advenchen Laboratories (Inst); Amgen/Dompé (Inst); Arog (Inst); Bayer (Inst); Blueprint Medicines (Inst); Boehringer Ingelheim (Inst); Boehringer Ingelheim (Inst); Daiihi Sankyo (Inst); Deciphera (Inst); Eisai (Inst); Epizyme (Inst); GlaxoSmithKline (Inst); Karyopharm Therapeutics (Inst); Lilly (Inst); Novartis (Inst); Pfizer (Inst); PharmaMar (Inst); Rain Therapeutics (Inst)
 
Carlo Morosi
No Relationships to Disclose
 
Luigi Mariani
No Relationships to Disclose
 
Giacomo Giulio Baldi
No Relationships to Disclose